Yanhong Deng

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Role: lead

Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer

Role: lead

Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)

Role: lead

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

Role: lead

Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer

Role: lead

Clinical Relevance of Pathologic Regression IN Lymph Node for Locally Advanced Rectal Cancer

Role: lead

Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer

Role: lead

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Role: lead

Urinary Retention Following taTME VS laTME Total Mesorectal Excision for Rectal Cancer

Role: lead

Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors

Role: lead

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

Role: lead

Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)

Role: lead

Bacteriological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.

Role: lead

Oncological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.

Role: lead

PRP Prevents Recurrence of Intrauterine Adhesions

Role: lead

Local Excision Versus Total Mesorectal Excision In Pathological Complete Response (ypT0-1cN0) Mid- Or Low-Rectal Cancer After Neoadjuvant Therapy

Role: lead